Dreams of simple, reliable and scalable processes for the much-hyped cell therapy market have generated demand for cost-effective, GMP-compliant manufacturing methods. The drug-screening market is also hungry for material that will allow the establishment of human cell disease models. A growing number of companies are now trying to coax induced pluripotent stem cells (iPSCs) into specific cells needed for clinical trials. Others are seeking the same goal through direct transdifferentiation protocols. What method will prove superior?
Illumina embraces Roche
Latest NewsTwelve years after Roche’s $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing.
Incyte licenses Morphosys’ tafasitamab in US$2bn deal
Latest NewsIncyte Corp. has signed a global license agreement for commercialisation of Morphosys AG’s anti-CD-19 programme tafasitamab.
Novadiscovery takes off with €5 Series A financing
Latest NewsIn silico clinical trials pioneer Novadiscovery SA has raised €5m in a series A financing led by Swiss Debiopharm Innovation Fund.
Playing God with the fates of cells
BackgroundDreams of simple, reliable and scalable processes for the much-hyped cell therapy market have generated demand for cost-effective, GMP-compliant manufacturing methods. The drug-screening market is also hungry for material that will allow the establishment of human cell disease models. A growing number of companies are now trying to coax induced pluripotent stem cells (iPSCs) into specific cells needed for clinical trials. Others are seeking the same goal through direct transdifferentiation protocols. What method will prove superior?
Alderaan Biotechnology raise €18.5m in Series A financing
Latest NewsFollowing a €1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised €18.5m in a Series A round led by Advent France Biotechnology and Medicxi.
North Sea Therapeutics raises US$40m in Series B
Latest NewsNorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate.
Merck and 4SC collaborate in immunooncology
Latest News4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Merck’s checkpoint blocker avelumab plus 4SC’s HDAC I blocker domatinostat.
The biotech boost – when, if not now?
BackgroundDespite the threat of a looming climate catastrophe, low oil prices and giant industrial conglomerates addicted to fossil resources continue to stifle industrial biotechnology products and innovation. The European Biotechnology Network is now providing a foot up for companies that want to help themselves by launching three very different projects aimed at pushing the bioeconomy forward.
Novo Holdings invest US$12m in AMR companies
Latest NewsMutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund.
Fighting sepsis mortality
Latest NewsCritical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality.